{"success":true,"data":{"pressRelease":{"id":"8945","rtpr_id":"nGNX3k4Njn","ticker":"BIVI","exchange":"NASDAQ","all_tickers":["BIVI"],"title":"BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026","author":"Globe Newswire","published_at":"2026-04-27T12:00:00.481Z","article_body":"CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:\nBIVI) (“BioVie” or the “Company”), a clinical-stage company developing\ninnovative drug therapies for neurological and neurodegenerative diseases,\ntoday announced that it will host a virtual key opinion leader (KOL) event on\nThursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH\n(Brown University Warren Alpert Medical School, Providence VA Medical Center),\nwho will join company management to discuss how bezisterim’s mechanism of\naction could potentially address the pathology and progression of\nneurodegenerative diseases, including Parkinson’s disease. To\nregister, click here\n(https://www.globenewswire.com/Tracker?data=xHZzFo-O_ipxiaIdrwVkN1vor9E_78osu6n9m5PR4dJrdmPdClHEc2d0BRGvfZMFjHIeKmEfAPR9_txTofUiS7tbgkeuOA-oDb_r3N20gqQ=).\n\nThe event will provide an update on BioVie's Phase 2 trial evaluating\nbezisterim (NE3107), an investigational drug candidate, for the treatment of\nParkinson's disease. Bezisterim is a novel, orally-administered small molecule\nthat, in preclinical and early clinical studies, has demonstrated potential to\nreduce insulin resistance and selectively inhibit inflammation-driven ERK- and\nNF-κB-stimulated inflammatory mediators without inhibiting their homeostatic\nfunctions. Inflammation and the associated insulin resistance contribute\nsignificantly to the development and progression of Parkinson's symptoms.\n\nA live question and answer session will follow the formal presentations.\n\nAbout Suzanne de la Monte, MD, MPH\n\nSuzanne de la Monte, MD, MPH is Professor in Pathology and Laboratory\nMedicine, Neurology, & Neurosurgery at the Warren Alpert Medical School of\nBrown University and Chief of Pathology & Laboratory Medicine at the\nProvidence VA Medical Center. Dr. de la Monte is also a medical staff member\nat the Rhode Island Hospital and Women and Infants Hospital of Rhode Island\nand formerly a research fellow at the National Institutes of Health. She\nreceived residency training in Anatomic and Pediatric Pathology at Johns\nHopkins and fellowship training in Neuropathology at the Massachusetts General\nHospital (MGH). Dr. de la Monte leads programs in basic, translational, and\nclinical research on mechanisms and consequences of brain insulin resistance\nand metabolic dysfunction and coined the term ‘Type 3 Diabetes’. She has\nover 300 peer-reviewed articles published.\n\nAbout Bezisterim\n\nBezisterim (NE3107) is an investigational oral drug that crosses the\nblood-brain barrier and works to reduce inflammation and improve insulin\nsensitivity without suppressing the immune system and with a low risk of\ndrug-drug interactions. By modulating key pathways involved in\nneuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic\npotential in several disease indications, including Parkinson’s disease,\nLong COVID, and Alzheimer’s disease.\n\nIn Parkinson’s disease, BioVie has completed a Phase 2 study in which\npatients with moderate- to severe stage Parkinson’s disease taking\nbezisterim with levodopa had better motor control and reported fewer morning\nsymptoms compared to those taking levodopa alone. Few drug-related side\neffects were observed. The current SUNRISE-PD is evaluating whether bezisterim\nalone can help improve motor and non-motor symptoms in Parkinson’s patients\nwho have not been treated with carbidopa/levodopa. Topline results are\nexpected in mid-2026.\n\nFor Long COVID, the ADDRESS-LC trial is enrolling about 200 patients to\nevaluate whether bezisterim may help reduce brain fog, fatigue, and other\nlingering neurological symptoms associated with Long COVID. The hypotheses\nbeing studied is that these symptoms may be triggered by persistent\ncirculation of spike protein fragments that trigger inflammation via NFκB\nactivation (which bezisterim has been shown to modulate). Topline data is\nexpected mid-2026.\n\nIn Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3\ntrials. Preliminary data from these trials suggest improvements in cognition\nand biomarkers, supporting further trials to evaluate its potential as a\ntherapy for the six million Americans living with Alzheimer’s.\n\nAbout BioVie Inc.\n\nBioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company\nfocused on developing therapies for neurological disorders and advanced liver\ndisease. Its lead investigational drug candidate, bezisterim (NE3107), targets\nneuroinflammation and insulin resistance, which are believed to be key drivers\nof Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied\nfor Long COVID, where persistent inflammation is thought to underlie symptoms\nsuch as brain fog and fatigue.\n\nIn liver disease, BioVie is advancing BIV201, a continuous infusion of\nterlipressin treatment that has received FDA Orphan and Fast Track\ndesignations. The active agent is approved in the U.S. and in about 40\ncountries for related complications of advanced liver cirrhosis, and the\nCompany plans to study BIV201 in a Phase 3 trial for the reduction of further\ndecompensation in patients with cirrhosis and ascites. For more information,\nvisit www.bioviepharma.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, which may be\nidentified by words such as \"expect,\" \"look forward to,\" \"anticipate,\"\n\"intend,\" \"plan,\" \"believe,\" \"seek,\" \"estimate,\" \"will,\" \"project,\"\n“potential,” “may,” or words of similar meaning. Although BioVie Inc.\nbelieves such forward-looking statements are based on reasonable assumptions,\nit can give no assurance that its expectations will be attained. Actual\nresults may vary materially from those expressed or implied by the statements\nherein due to risk related to the early stage of development of bezisterim and\nother product candidates the Company's ability to successfully raise\nsufficient capital on reasonable terms or at all, available cash on hand and\ncontractual and statutory limitations that could impair our ability to pay\nfuture dividends, our ability to complete our pre-clinical or clinical studies\nand to obtain approval for our product candidates, the possibility that\nclinical trial results may not be indicative of results in subsequent or\nlarger tirals, our ability to successfully defend potential future litigation,\nchanges in local or national economic conditions as well as various additional\nrisks, many of which are now unknown and generally out of the Company's\ncontrol, and which are detailed from time to time in reports filed by the\nCompany with the SEC, including quarterly reports on Form 10-Q, reports on\nForm 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any\nduty to update any statements contained herein (including any forward-looking\nstatements), except as required by law.\n\nFor Investor Relations Inquiries:\n\nContact:\nChuck Padala\nManaging Director, LifeSci Advisors, LLC\nchuck@lifesciadvisors.com\n\nFor Media Inquiries:\n\nContact:\nMelyssa Weible\nManaging Partner, Elixir Health Public Relations \nmweible@elixirhealthpr.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f437d04b-c089-46eb-bca8-7ef64f68bc9b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3k4Njn","title":"BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026","author":"Globe Newswire","ticker":"BIVI","created":"2026-04-27T12:00:00.481Z","tickers":["BIVI"],"exchange":"NASDAQ","article_body":"CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:\nBIVI) (“BioVie” or the “Company”), a clinical-stage company developing\ninnovative drug therapies for neurological and neurodegenerative diseases,\ntoday announced that it will host a virtual key opinion leader (KOL) event on\nThursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH\n(Brown University Warren Alpert Medical School, Providence VA Medical Center),\nwho will join company management to discuss how bezisterim’s mechanism of\naction could potentially address the pathology and progression of\nneurodegenerative diseases, including Parkinson’s disease. To\nregister, click here\n(https://www.globenewswire.com/Tracker?data=xHZzFo-O_ipxiaIdrwVkN1vor9E_78osu6n9m5PR4dJrdmPdClHEc2d0BRGvfZMFjHIeKmEfAPR9_txTofUiS7tbgkeuOA-oDb_r3N20gqQ=).\n\nThe event will provide an update on BioVie's Phase 2 trial evaluating\nbezisterim (NE3107), an investigational drug candidate, for the treatment of\nParkinson's disease. Bezisterim is a novel, orally-administered small molecule\nthat, in preclinical and early clinical studies, has demonstrated potential to\nreduce insulin resistance and selectively inhibit inflammation-driven ERK- and\nNF-κB-stimulated inflammatory mediators without inhibiting their homeostatic\nfunctions. Inflammation and the associated insulin resistance contribute\nsignificantly to the development and progression of Parkinson's symptoms.\n\nA live question and answer session will follow the formal presentations.\n\nAbout Suzanne de la Monte, MD, MPH\n\nSuzanne de la Monte, MD, MPH is Professor in Pathology and Laboratory\nMedicine, Neurology, & Neurosurgery at the Warren Alpert Medical School of\nBrown University and Chief of Pathology & Laboratory Medicine at the\nProvidence VA Medical Center. Dr. de la Monte is also a medical staff member\nat the Rhode Island Hospital and Women and Infants Hospital of Rhode Island\nand formerly a research fellow at the National Institutes of Health. She\nreceived residency training in Anatomic and Pediatric Pathology at Johns\nHopkins and fellowship training in Neuropathology at the Massachusetts General\nHospital (MGH). Dr. de la Monte leads programs in basic, translational, and\nclinical research on mechanisms and consequences of brain insulin resistance\nand metabolic dysfunction and coined the term ‘Type 3 Diabetes’. She has\nover 300 peer-reviewed articles published.\n\nAbout Bezisterim\n\nBezisterim (NE3107) is an investigational oral drug that crosses the\nblood-brain barrier and works to reduce inflammation and improve insulin\nsensitivity without suppressing the immune system and with a low risk of\ndrug-drug interactions. By modulating key pathways involved in\nneuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic\npotential in several disease indications, including Parkinson’s disease,\nLong COVID, and Alzheimer’s disease.\n\nIn Parkinson’s disease, BioVie has completed a Phase 2 study in which\npatients with moderate- to severe stage Parkinson’s disease taking\nbezisterim with levodopa had better motor control and reported fewer morning\nsymptoms compared to those taking levodopa alone. Few drug-related side\neffects were observed. The current SUNRISE-PD is evaluating whether bezisterim\nalone can help improve motor and non-motor symptoms in Parkinson’s patients\nwho have not been treated with carbidopa/levodopa. Topline results are\nexpected in mid-2026.\n\nFor Long COVID, the ADDRESS-LC trial is enrolling about 200 patients to\nevaluate whether bezisterim may help reduce brain fog, fatigue, and other\nlingering neurological symptoms associated with Long COVID. The hypotheses\nbeing studied is that these symptoms may be triggered by persistent\ncirculation of spike protein fragments that trigger inflammation via NFκB\nactivation (which bezisterim has been shown to modulate). Topline data is\nexpected mid-2026.\n\nIn Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3\ntrials. Preliminary data from these trials suggest improvements in cognition\nand biomarkers, supporting further trials to evaluate its potential as a\ntherapy for the six million Americans living with Alzheimer’s.\n\nAbout BioVie Inc.\n\nBioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company\nfocused on developing therapies for neurological disorders and advanced liver\ndisease. Its lead investigational drug candidate, bezisterim (NE3107), targets\nneuroinflammation and insulin resistance, which are believed to be key drivers\nof Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied\nfor Long COVID, where persistent inflammation is thought to underlie symptoms\nsuch as brain fog and fatigue.\n\nIn liver disease, BioVie is advancing BIV201, a continuous infusion of\nterlipressin treatment that has received FDA Orphan and Fast Track\ndesignations. The active agent is approved in the U.S. and in about 40\ncountries for related complications of advanced liver cirrhosis, and the\nCompany plans to study BIV201 in a Phase 3 trial for the reduction of further\ndecompensation in patients with cirrhosis and ascites. For more information,\nvisit www.bioviepharma.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, which may be\nidentified by words such as \"expect,\" \"look forward to,\" \"anticipate,\"\n\"intend,\" \"plan,\" \"believe,\" \"seek,\" \"estimate,\" \"will,\" \"project,\"\n“potential,” “may,” or words of similar meaning. Although BioVie Inc.\nbelieves such forward-looking statements are based on reasonable assumptions,\nit can give no assurance that its expectations will be attained. Actual\nresults may vary materially from those expressed or implied by the statements\nherein due to risk related to the early stage of development of bezisterim and\nother product candidates the Company's ability to successfully raise\nsufficient capital on reasonable terms or at all, available cash on hand and\ncontractual and statutory limitations that could impair our ability to pay\nfuture dividends, our ability to complete our pre-clinical or clinical studies\nand to obtain approval for our product candidates, the possibility that\nclinical trial results may not be indicative of results in subsequent or\nlarger tirals, our ability to successfully defend potential future litigation,\nchanges in local or national economic conditions as well as various additional\nrisks, many of which are now unknown and generally out of the Company's\ncontrol, and which are detailed from time to time in reports filed by the\nCompany with the SEC, including quarterly reports on Form 10-Q, reports on\nForm 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any\nduty to update any statements contained herein (including any forward-looking\nstatements), except as required by law.\n\nFor Investor Relations Inquiries:\n\nContact:\nChuck Padala\nManaging Director, LifeSci Advisors, LLC\nchuck@lifesciadvisors.com\n\nFor Media Inquiries:\n\nContact:\nMelyssa Weible\nManaging Partner, Elixir Health Public Relations \nmweible@elixirhealthpr.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f437d04b-c089-46eb-bca8-7ef64f68bc9b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-27T12:00:00.530005672Z","server_sent_at_ms":1777291200530},"received_at":"2026-04-27T12:00:00.585Z","source_url":null},"analysis":{"id":"6720","press_release_id":"8945","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"BioVie announced it will host a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss the mechanism of action and Phase 2 trial of bezisterim for Parkinson's disease.\n\nThe company remains on track for topline data from the Parkinson's study in mid-2026, while also enrolling about 200 patients for its ADDRESS-LC trial in Long COVID.\n\nBezisterim is an oral therapy targeting neuroinflammation and insulin resistance, and BioVie is concurrently developing BIV201, a treatment for advanced liver disease.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{"customDimensions":{"topline_data_timing":"mid-2026","long_covid_enrollment":"about 200 patients"}},"namedEntities":{"people":[{"name":"Suzanne de la Monte","role":"Professor, Brown University; Chief of Pathology, Providence VA Medical Center"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors, LLC"},{"name":"Melyssa Weible","role":"Managing Partner, Elixir Health Public Relations"}],"products":["Bezisterim","NE3107","BIV201","Levodopa","Carbidopa"],"companies":[{"name":"BioVie Inc.","ticker":"BIVI"},{"name":"Brown University","relationship":"institution"},{"name":"Providence VA Medical Center","relationship":"institution"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"Elixir Health Public Relations","relationship":"public relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of a virtual KOL event and reiteration of existing clinical trial timelines (mid-2026) without new data, regulatory decisions, or financial updates."},"tickerRelevance":{"others":[],"primary":"BIVI"},"globalImportance":5,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"webinar_announcement","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"BioVie announced it will host a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss the mechanism of action and Phase 2 trial of bezisterim for Parkinson's disease.\n\nThe company remains on track for topline data from the Parkinson's study in mid-2026, while also enrolling about 200 patients for its ADDRESS-LC trial in Long COVID.\n\nBezisterim is an oral therapy targeting neuroinflammation and insulin resistance, and BioVie is concurrently developing BIV201, a treatment for advanced liver disease.","key_figures":{"customDimensions":{"topline_data_timing":"mid-2026","long_covid_enrollment":"about 200 patients"}},"named_entities":{"people":[{"name":"Suzanne de la Monte","role":"Professor, Brown University; Chief of Pathology, Providence VA Medical Center"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors, LLC"},{"name":"Melyssa Weible","role":"Managing Partner, Elixir Health Public Relations"}],"products":["Bezisterim","NE3107","BIV201","Levodopa","Carbidopa"],"companies":[{"name":"BioVie Inc.","ticker":"BIVI"},{"name":"Brown University","relationship":"institution"},{"name":"Providence VA Medical Center","relationship":"institution"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"Elixir Health Public Relations","relationship":"public relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-27T14:30:23.221Z","global_importance":5,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"webinar_announcement","sectorWeight":"biotech"}},"durationMs":132262,"modelName":"glm-4.7"}}